👤 J. Valdez

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2
Articles
3
Name variants
Also published as: Crystal E Valdez, Crystal E. Valdez,
articles
Y. Park, P. Xu, D.M. Parkin +324 more · 2022 · Biomedicines · MDPI · added 2026-04-20
Y. Park, P. Xu, D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, N. Andre, W. Schmiegel, B. Gustavsson, G. Carlsson, D. Machover, N. Petrelli, A. Roth, H. Schmoll, K. Tveit, F. Gibson, G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, S. Sarkar, L. Bao, S. Hazari, S. Mehra, D. Kaushal, K. Moroz, S. Dash, Z. Yuan, X. Shi, Y. Qi, T. Jia, X. Yuan, Y. Zou, C. Liu, H. Yu, Y. Yuan, X. He, A.K. Pandurangan, D. Chao, W. Jiao, C. Yin, N. Jianyun, C. Ceshi, A. Guerrero-Zotano, I.A. Mayer, C.L. Arteaga, C. Han, G. Xing, M. Zhang, M. Zhong, Z. Han, C. He, X. Liu, Z. Zou, T. Tao, H. Li, X. Zhu, D.D. Sarbassov, S.M. Ali, D.M. Sabatini, D. Heras-Sandoval, J.M. Pérez-Rojas, J. Hernández-Damián, J. Pedraza-Chaverri, J. Roper, M.P. Richardson, W.V. Wang, L.G. Richard, W. Chen, E.M. Coffee, M.J. Sinnamon, L. Lee, P. Chen, R.T. Bronson, Y. Kondo, T. Kanzawa, R. Sawaya, S. Kondo, W. Li, Y. Zhou, J. Yang, H. Zhang, P. Zheng, Z. Wang, N. Wang, P. Liu, X. Xie, D. Zhang, W. Wang, X. Sun, D. Xu, C. Wang, Q. Zhang, H. Wang, W. Luo, Y. Chen, H. Chen, Z. Cao, Y. Yang, S. Yu, Y. Li, J. Huang, L. Xiong, S. Lei, C. Peng, M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, D.H. Suh, M.A. Kim, H. Kim, M. Kim, H.S. Kim, H.H. Chung, Y. Kim, Y.S. Song, J. Peng, Y. Cui, S. Xu, X. Wu, Y. Huang, W. Zhou, S. Wang, Z. Fu, H. Xie, G. Wang, Y. Yu, Y.Z. Wang, P.H. Yin, K. Xu, H. Bleiberg, P. Perego, J. Robert, W. Lian, M. Li, R.N. Seetharam, A. Sood, S. Goel, E. Martinez-Balibrea, A. Martínez-Cardús, A. Ginés, V. Ruiz de Porras, C. Moutinho, L. Layos, J.L. Manzano, C. Bugés, S. Bystrup, M. Esteller, P. Noordhuis, A.C. Laan, K. Van de Born, R.J. Honeywell, G.J. Peters, W. Sun, Y. Ge, J. Cui, B. Liu, W. Lu, M. Ma, Q. Yan, W. He, Y. Hu, L. Xia, W. Hou, J. Chai, H. Guo, J. Yu, S.H. Bae, J.H. Park, H.G. Choi, S.H. Kim, H.Y. Yoo, S.Y. Park, S.Y. Chang, G. Meyer, A. Czompa, C. Reboul, E. Stepania, A. Czegledi, I. Bak, G. Balla, J. Balla, A. Tosaki, I. Lekli, W. Cao, J. Li, K. Yang, D. Cao, I. Tanida, T. Ueno, E. Kominami, J.M. Woynarowski, S. Faivre, M.C. Herzig, B. Arnett, W.G. Chapman, A.V. Trevino, E. Raymond, S.G. Chaney, A. Vaisman, M. Varchenko, R. Teng, J. Zhou, B. Seifer, J. Shen, L. Wang, H.R. Kang, C.K. Jeon, S. Lim, J.I. Barrasa, A. Santiago-Gómez, N. Olmo, M.A. Lizarbe, J. Turnay, A. Derjuga, C. Richard, M. Crosato, P.S. Wright, L. Chalifour, J. Valdez, A. Barraso, H.A. Crissman, W. Nishioka, E.M. Bradbury, Q. Shi, S. Li, L. Jin, H. Lai, Y. Wu, Z. Cai, M. Zhu, Q. Li, C.W. Yao, K.A. Kang, M.J. Piao, Y.S. Ryu, P.M.D.J. Fernando, M.C. Oh, J.E. Park, K. Shilnikova, S.-Y. Na, S.U. Jeong, Y. Zhao, X. Hu, Y. Liu, S. Dong, Z. Wen, S. Zhang, Q. Huang, M. Shi, V.G.A. Arciuch, M.A. Russo, K.S. Kang, A.D. Cristofano, L. Vucicevic, M. Misirkic, J. Kristina, U. Vilimanovich, E. Sudar, E. Isenovic, M. Prica, L. Harhaji-Trajkovic, T. Kravic-Stevovic, B. Vladimir, S. Lee, W. Yang, D.K. Kim, M. Shin, K.U. Choi, D.S. Suh, Y.H. Kim, T.-H. Hwang, J.H. Kim, C. Wu, Y. Chao, S. Shiah, W. Lin, M. Mouradian, K.D. Kikawa, B.P. Dranka, S.M. Komas, B. Kalyanaraman, R.S. Pardini, F. Gharibpoor, S.K. Zonouzi, S. Razi, H. Rezaei, Z. Yao, F. Xie, Z. Liang, W. Xu, H. Zhou, L.-H. Qu, D. Catanzaro, D. Gabbia, V. Cocetta, M. Biagi, E. Ragazzi, M. Montopoli, M. Carrara, X. Cao, L. Fang, S. Gibbs, Z. Dai, P. Wen, X. Zheng, W. Sadee, D. Sun, E.E. Mendoza, M.G. Pocceschi, X. Kong, D.B. Leeper, J. Caro, K.H. Limesand, R. Burd, E. Domenech, C. Maestre, L. Esteban-Martínez, D. Partida, R. Pascual, G. Fernandez-Miranda, E. Seco, R. Campos-Olivas, M. Perez, D. Megias Show less
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In Show more
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug concentration to 2.5 μM. The inhibitory concentrations of cell growth by 50% (IC 50 ) of oxaliplatin were 4.40–12.7-fold significantly higher in OR CRC cells as compared to their respective parental (PT) CRC cells. Phospho-Akt and phospho-mammalian target of rapamycin (mTOR) decreased in PT CRC cells but was overexpressed in OR CRC cells in response to oxaliplatin. In addition, an oxaliplatin-mediated decrease in phospho-AMP-activated protein kinase (AMPK) in PT CRC cells induced autophagy. Contrastingly, an increased phospho-AMPK in OR CRC cells was accompanied by a decrease in LC3B, further inducing the activity of glycolytic enzymes, such as glucose transporter 1 (GLUT1), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) and phosphofructokinase 1 (PFK1), to mediate cell survival. Inhibition of AMPK in OR CRC cells induced autophagy through inactivation of Akt/mTOR pathway and a decrease in GLUT1, PFKFB3, and PFK1. Collectively, targeting AMPK may provide solutions to overcome chemoresistance in OR CRC cells and restore chemosensitivity to anticancer drugs. Show less
📄 PDF DOI: 10.3390/biomedicines10112690
Pt amino-acid anticancer
Crystal E Valdez, Quentin A Smith, Michael R Nechay +1 more · 2014 · Accounts of Chemical Research · ACS Publications · added 2026-04-20
Natural metalloenzymes are often the most proficient catalysts in terms of their activity, selectivity, and ability to operate at mild conditions. However, metalloenzymes are occasionally surprising i Show more
Natural metalloenzymes are often the most proficient catalysts in terms of their activity, selectivity, and ability to operate at mild conditions. However, metalloenzymes are occasionally surprising in their selection of catalytic metals, and in their responses to metal substitution. Indeed, from the isolated standpoint of producing the best catalyst, a chemist designing from first-principles would likely choose a different metal. For example, some enzymes employ a redox active metal where a simple Lewis acid is needed. Such are several hydrolases. In other cases, substitution of a non-native metal leads to radical improvements in reactivity. For example, histone deacetylase 8 naturally operates with Zn(2+) in the active site but becomes much more active with Fe(2+). For β-lactamases, the replacement of the native Zn(2+) with Ni(2+) was suggested to lead to higher activity as predicted computationally. There are also intriguing cases, such as Fe(2+)- and Mn(2+)-dependent ribonucleotide reductases and W(4+)- and Mo(4+)-dependent DMSO reductases, where organisms manage to circumvent the scarcity of one metal (e.g., Fe(2+)) by creating protein structures that utilize another metal (e.g., Mn(2+)) for the catalysis of the same reaction. Naturally, even though both metal forms are active, one of the metals is preferred in every-day life, and the other metal variant remains dormant until an emergency strikes in the cell. These examples lead to certain questions. When are catalytic metals selected purely for electronic or structural reasons, implying that enzymatic catalysis is optimized to its maximum? When are metal selections a manifestation of competing evolutionary pressures, where choices are dictated not just by catalytic efficiency but also by other factors in the cell? In other words, how can enzymes be improved as catalysts merely through the use of common biological building blocks available to cells? Addressing these questions is highly relevant to the enzyme design community, where the goal is to prepare maximally efficient quasi-natural enzymes for the catalysis of reactions that interest humankind. Due to competing evolutionary pressures, many natural enzymes may not have evolved to be ideal catalysts and can be improved for the isolated purpose of catalysis in vitro when the competing factors are removed. The goal of this Account is not to cover all the possible stories but rather to highlight how variable enzymatic catalysis can be. We want to bring up possible factors affecting the evolution of enzyme structure, and the large- and intermediate-scale structural and electronic effects that metals can induce in the protein, and most importantly, the opportunities for optimization of these enzymes for catalysis in vitro. Show less
📄 PDF DOI: 10.1021/ar500227u
Fe Ni Zn amino-acid catalysis